SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,637.41 (-2.86%)
DOW   29,254.89 (-2.25%)
QQQ   269.67 (-3.61%)
AAPL   140.41 (-3.45%)
MSFT   234.44 (-5.00%)
META   133.25 (-4.18%)
GOOGL   98.69 (-2.69%)
AMZN   114.79 (-4.58%)
TSLA   224.00 (-5.93%)
NVDA   121.69 (-7.32%)
NIO   13.68 (-7.38%)
BABA   81.21 (-3.69%)
AMD   59.35 (-12.53%)
T   15.04 (-1.83%)
MU   53.06 (-2.86%)
CGC   2.81 (-25.07%)
F   12.16 (-1.62%)
GE   64.28 (-2.93%)
DIS   96.99 (-3.05%)
AMC   6.47 (-9.13%)
PYPL   90.17 (-4.50%)
PFE   42.31 (-1.81%)
NFLX   228.60 (-4.76%)
S&P 500   3,637.41 (-2.86%)
DOW   29,254.89 (-2.25%)
QQQ   269.67 (-3.61%)
AAPL   140.41 (-3.45%)
MSFT   234.44 (-5.00%)
META   133.25 (-4.18%)
GOOGL   98.69 (-2.69%)
AMZN   114.79 (-4.58%)
TSLA   224.00 (-5.93%)
NVDA   121.69 (-7.32%)
NIO   13.68 (-7.38%)
BABA   81.21 (-3.69%)
AMD   59.35 (-12.53%)
T   15.04 (-1.83%)
MU   53.06 (-2.86%)
CGC   2.81 (-25.07%)
F   12.16 (-1.62%)
GE   64.28 (-2.93%)
DIS   96.99 (-3.05%)
AMC   6.47 (-9.13%)
PYPL   90.17 (-4.50%)
PFE   42.31 (-1.81%)
NFLX   228.60 (-4.76%)
S&P 500   3,637.41 (-2.86%)
DOW   29,254.89 (-2.25%)
QQQ   269.67 (-3.61%)
AAPL   140.41 (-3.45%)
MSFT   234.44 (-5.00%)
META   133.25 (-4.18%)
GOOGL   98.69 (-2.69%)
AMZN   114.79 (-4.58%)
TSLA   224.00 (-5.93%)
NVDA   121.69 (-7.32%)
NIO   13.68 (-7.38%)
BABA   81.21 (-3.69%)
AMD   59.35 (-12.53%)
T   15.04 (-1.83%)
MU   53.06 (-2.86%)
CGC   2.81 (-25.07%)
F   12.16 (-1.62%)
GE   64.28 (-2.93%)
DIS   96.99 (-3.05%)
AMC   6.47 (-9.13%)
PYPL   90.17 (-4.50%)
PFE   42.31 (-1.81%)
NFLX   228.60 (-4.76%)
S&P 500   3,637.41 (-2.86%)
DOW   29,254.89 (-2.25%)
QQQ   269.67 (-3.61%)
AAPL   140.41 (-3.45%)
MSFT   234.44 (-5.00%)
META   133.25 (-4.18%)
GOOGL   98.69 (-2.69%)
AMZN   114.79 (-4.58%)
TSLA   224.00 (-5.93%)
NVDA   121.69 (-7.32%)
NIO   13.68 (-7.38%)
BABA   81.21 (-3.69%)
AMD   59.35 (-12.53%)
T   15.04 (-1.83%)
MU   53.06 (-2.86%)
CGC   2.81 (-25.07%)
F   12.16 (-1.62%)
GE   64.28 (-2.93%)
DIS   96.99 (-3.05%)
AMC   6.47 (-9.13%)
PYPL   90.17 (-4.50%)
PFE   42.31 (-1.81%)
NFLX   228.60 (-4.76%)
NASDAQ:GILD

Gilead Sciences - GILD Stock Forecast, Price & News

$64.75
-0.20 (-0.31%)
(As of 10/7/2022 02:16 PM ET)
Add
Compare
Today's Range
$64.00
$65.09
50-Day Range
$59.54
$68.01
52-Week Range
$57.17
$74.12
Volume
294,045 shs
Average Volume
8.64 million shs
Market Capitalization
$81.16 billion
P/E Ratio
19.74
Dividend Yield
4.46%
Price Target
$73.94

Gilead Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
14.3% Upside
$73.94 Price Target
Short Interest
Healthy
1.33% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.29mentions of Gilead Sciences in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-1.82%
From $6.61 to $6.49 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

Medical Sector

24th out of 1,075 stocks

Biological Products, Except Diagnostic Industry

3rd out of 170 stocks

GILD stock logo

About Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

GILD Stock News Headlines

Gilead Sciences, Inc. (NASDAQ:GILD) Looks Just Right
MicroCap With Big Potential
Company has ‘war chest’ of cash and innovative products in fast-growing market.
MicroCap With Big Potential
Company has ‘war chest’ of cash and innovative products in fast-growing market.
Gilead Sciences: Becoming A Cure
Gilead Sciences (NASDAQ: GILD)
A Dive Into Gilead Sciences' New HIV Medication
See More Headlines
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

GILD Company Calendar

Last Earnings
8/02/2022
Ex-Dividend for 9/29 Dividend
9/14/2022
Dividend Payable
9/29/2022
Today
10/07/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GILD
CUSIP
37555810
Employees
14,400
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$73.94
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$56.00
Forecasted Upside/Downside
+14.2%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
15 Analysts

Profitability

Net Income
$6.23 billion
Pretax Margin
20.16%

Debt

Sales & Book Value

Annual Sales
$27.31 billion
Cash Flow
$8.87 per share
Book Value
$16.79 per share

Miscellaneous

Outstanding Shares
1,253,370,000
Free Float
1,251,362,000
Market Cap
$81.16 billion
Optionable
Optionable
Beta
0.31

Social Links


Key Executives

  • Mr. Daniel P. O'Day (Age 58)
    Chairman & CEO
    Comp: $6.09M
  • Mr. Andrew D. DickinsonMr. Andrew D. Dickinson (Age 52)
    Exec. VP & CFO
    Comp: $2.55M
  • Ms. Johanna MercierMs. Johanna Mercier (Age 52)
    Chief Commercial Officer
    Comp: $2.92M
  • Dr. Merdad V. Parsey M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $2.68M
  • Ms. Diane E. WilfongMs. Diane E. Wilfong (Age 60)
    Sr. VP, Corp. Controller & Chief Accounting Officer
  • Ms. Jacquie Ross C.F.A.
    VP of Investor Relations
  • Ms. Deborah H. Telman (Age 57)
    Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
  • Ms. Jyoti K. Mehra
    Exec. VP of HR
  • Dr. Michael Quigley Ph.D.
    Sr. VP of Research Biology
  • Dr. Linda Slanec Higgins Ph.D. (Age 60)
    Sr. VP & Head of External Innovation













GILD Stock - Frequently Asked Questions

Should I buy or sell Gilead Sciences stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings
or view top-rated stocks.

What is Gilead Sciences' stock price forecast for 2022?

15 Wall Street analysts have issued 1 year target prices for Gilead Sciences' shares. Their GILD share price forecasts range from $56.00 to $90.00. On average, they predict the company's share price to reach $73.94 in the next year. This suggests a possible upside of 13.8% from the stock's current price.
View analysts price targets for GILD
or view top-rated stocks among Wall Street analysts.

How have GILD shares performed in 2022?

Gilead Sciences' stock was trading at $72.61 at the beginning of 2022. Since then, GILD shares have decreased by 10.5% and is now trading at $64.95.
View the best growth stocks for 2022 here
.

When is Gilead Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our GILD earnings forecast
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.07. The biopharmaceutical company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $5.88 billion. Gilead Sciences had a net margin of 15.03% and a trailing twelve-month return on equity of 42.92%.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Tuesday, August 2nd. Investors of record on Thursday, September 15th will be given a dividend of $0.73 per share on Thursday, September 29th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.50%. The ex-dividend date of this dividend is Wednesday, September 14th.
Read our dividend analysis for GILD
.

Is Gilead Sciences a good dividend stock?

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 4.46%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 89.02%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GILD will have a dividend payout ratio of 44.99% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of $6.35-$6.75 for the period, compared to the consensus earnings per share estimate of $6.57. The company issued revenue guidance of $24.50 billion-$25.00 billion, compared to the consensus revenue estimate of $24.57 billion.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Confluence Investment Management LLC (0.11%), Meyer Handelman Co. (0.03%), Capital Investment Advisors LLC (0.02%), Gulf International Bank UK Ltd (0.02%), Thomasville National Bank (0.01%) and First Financial Bank Trust Division (0.01%). Insiders that own company stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends
.

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $64.95.

How much money does Gilead Sciences make?

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $81.41 billion and generates $27.31 billion in revenue each year. The biopharmaceutical company earns $6.23 billion in net income (profit) each year or $3.28 on an earnings per share basis.

How many employees does Gilead Sciences have?

The company employs 14,400 workers across the globe.

Does Gilead Sciences have any subsidiaries?
The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (GSR) S.R.L., Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Colombia S.A.S., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland Unlimited Company, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, MYR GmbH, MYR Pharmaceuticals France SAS, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..
Read More
How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.

This page (NASDAQ:GILD) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.